Recon: FDA approves Verrica’s Ycanth, first treatment for common skin disorder; Roche inks $2.8B deal with Alnyam
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy